Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways

Keloid disease is characterized by hyperproliferation of responsive fibroblasts with vigorously continuous synthesis of extracellular matrix (ecm) components. although the process by which keloids develop is poorly understood, most theories of the etiology are referred to fibroblast dysfunction. a central event in dermal repair is the release of growth factors in response to skin injury, which leads to the dysregulation of several crucial pathways that initiate the activation of keloid fibroblasts (kfs) and promote ecm accumulation. hence, strategies aimed at reducing the production of these cytokines and/or disrupting their intracellular signal transduction have potential clinical significance for curing keloid. as the first oral multikinase inhibitor, sorafenib blocks a number of intracellular signaling pathways which are also pivotal for keloid pathogenesis. therefore, evaluation of the effects of sorafenib on keloid disease seems timely and pertinent. in this study, we reported the identification of sorafenib that antagonized tgf-β/smad and mapk/erk signaling pathways in primary kfs. impressively, treatment with sorafenib inhibited kf cell proliferation, migration, and invasion, and simultaneously reduced collagen production in kfs. furthermore, we present ex vivo evidence that sorafenib induced the arrest of kf migration, the inhibition of angiogenesis, and the reduction of collagen accumulation. these preclinical observations suggest that sorafenib deserves systematic exploration as a candidate agent for the future treatment of keloids.